Achillion, Idenix could miss hep-C merger bonanza
February 01, 2012 at 00:01 AM EST
Investors tantalized by a recent string of lucrative takeover offers for hepatitis C drug-developers shouldn’t assume that an eye-popping bid for Idenix Pharmaceuticals and Achillion Pharmaceuticals is just around the corner, according to biotech analysts.